MedPath

Rapid Iron Infusion Study- a randomised controlled trial (RCT) of the treatment of iron deficiency anaemia in children (RIIS)

Phase 3
Recruiting
Conditions
Childhood Iron Deficiency Anaemia
Blood - Anaemia
Diet and Nutrition - Other diet and nutrition disorders
Registration Number
ACTRN12617001273370
Lead Sponsor
Menzies School of Health Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
226
Inclusion Criteria

Aboriginal or Torres Strait Islander children with Iron deficiency anaemia (a haemoglobin level (Hb) <110g/L and mean cell volume (MCV) <75fL), will be eligible to participate in the randomised trial if the treating clinician recommends parenteral iron treatment.

Exclusion Criteria

1) parenteral iron treatment or blood transfusion within the last 4 weeks; 2) known iron overload, haemoglobinopathy, haemolytic anaemia, aplastic anaemia, lymphoproliferative disease or current cancer treatment; 3) febrile >38 degree centigrade or very unwell or receiving phosphate supplementation at the time of discharge; 4) lack of access to a primary health provider in the NT; 5) allergy or hypersensitivity to Ferinject or any of its excipients; 6) known serious hypersensitivity to other parenteral iron products; 7) severe asthma, eczema or allergies; 8) not planning to remain resident in the NT for 12 months.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Haemoglobin level [At the time of anaemia requiring additional iron treatment or at the final assessment at 6-9 months post randomisation (whichever is first). <br><br>]
Secondary Outcome Measures
NameTimeMethod
Clinical treatment failure[ Clinical treatment failure as defined by either anaemia requiring additional treatment or haemoglobin <110g/L at the final assessment at 6-9 months post randomisation<br>];Proportion of adverse drug reactions (urticaria, headache, nausea, vomiting etc) and serious adverse events (anaphylaxis)[ Study outcome will be gathered from remote communities within 6-9 months post randomisation];Data will be collected for the number of sick visits and well visits with reasons for attendance (primary and secondary diagnoses) in the clinic. The illnesses documented in the clinical record and any admissions to hospital will also be checked. [within 6-9 months post randomisation];Rates of attendance at the local health centre[within 6-9 months post randomisation]
© Copyright 2025. All Rights Reserved by MedPath